Respiratory Infections News

“Soap, water and common sense are the best disinfectants.” - William Osler.

Sanofi and GSK announced Wednesday that they will submit data from booster and phase 3 efficacy trials to support authorization of their two-dose protein-based COVID-19 vaccine.

The interval between the first and second doses of the Pfizer-BioNTech and Moderna COVID-19 vaccines can be up to 8 weeks for certain people, the CDC said in updated interim guidance.

The risk for multisystem inflammatory syndrome in children, or MIS-C, is reduced to just one in a million when a person receives at least one dose of COVID-19 vaccine, researchers reported in The Lancet Child & Adolescent Health.

Moderna announced Tuesday that it has initiated a phase 3 study of its investigational messenger RNA-based vaccine for RSV.

Health care workers with a nasopharyngeal swab positive for SARS-CoV-2 were more likely to report long COVID symptoms after 6 months than negative controls in a study conducted in more than 20 Swiss hospitals.

Researchers evaluated the immune responses of a few dozen people who received three doses of a COVID-19 messenger RNA vaccine and found, as other have, that a booster shot can protect people infected with a variant from becoming very ill.

Veterans who survived COVID-19 were at increased risk for mental health, substance use and sleep disorders up to 1 year later, data showed.

In its latest public campaign to encourage parents to vaccinate their children, the AAP launched a new series of videos that address common questions parents have about childhood vaccines.

A 500 mg intramuscular injection of sotrovimab was noninferior to an IV infusion of the investigational monoclonal antibody for the treatment of mild to moderate COVID-19 in a phase 3 trial, investigators reported.